The use of BCL2 inhibitors, like VEN, in combination with hypomethylating agents (HMAs) has been associated with increased overall survival (OS) in AML patients over 65 years, who have BCL2 overexpression (9). This evidence concerns the gene BCL2 and acute myeloid leukemia.